Skip to main content Accessibility help
×
Hostname: page-component-77c89778f8-sh8wx Total loading time: 0 Render date: 2024-07-20T18:35:42.768Z Has data issue: false hasContentIssue false

10 - Treatment

Published online by Cambridge University Press:  10 September 2009

Joe T. R. Clarke
Affiliation:
University of Toronto
Get access

Summary

The purpose of this chapter is to present some general principles of the management of inherited metabolic diseases using specific examples to illustrate various points. It is not meant to be a detailed guide to the specific treatment of any particular disease. Instead, it is intended to provide a conceptual scaffold to aid in understanding the strategy behind the management of various inborn errors of metabolism, particularly strategies involving environmental manipulation.

A logical approach to treatment would be to determine how various point defects in metabolism cause disease, and to reverse or neutralize them, either by dietary, pharmacologic, or some other form of metabolic manipulation. However, in many cases, our understanding of how a particular point defect in metabolism produces disease is still incomplete. Often the abnormality is metabolically or physically inaccessible to environmental manipulation. In the discussion to follow, examples are provided of how rational approaches to treatment grew out of an understanding of the primary and secondary consequences of inborn errors of metabolism. The emphasis is on instances in which treatment is at least partially successful.

Control of accumulation of substrate

When disease is caused by accumulation of the substrate of a reaction that is impaired as a result of deficiency of an enzyme or transport protein, a reasonable approach to treatment would be to try to control levels of the toxic metabolite, either by decreasing its accumulation or accelerating its removal by alternative reactions.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baldellou, A., Andria, G., Campbell, P. E., et al. (2004). Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. European Journal of Pediatrics, 163, 67–75.CrossRefGoogle Scholar
Bosch, A. M., Grootenhuis, M. A., Bakker, H. D., Heijmans, H. S., Wijburg, F. A., Last, B. F. (2004). Living with classical galactosemia: health-related quality of life consequences. Pediatrics, 113, e423–8.CrossRefGoogle ScholarPubMed
Brown, A. S., Fernhoff, P. M., Waisbren, S. E., et al. (2002). Barriers to successful dietary control among pregnant women with phenylketonuria. Genetics in Medicine, 4, 84–9.CrossRefGoogle ScholarPubMed
Burdelski, M. & Ullrich, K. (1999). Liver transplantation in metabolic disorders: summary of the general discussion. European Journal of Pediatrics, 158 (Suppl 2), S95–S96.CrossRefGoogle ScholarPubMed
Cabrera-Salazar, M. A., Novelli, E. & Barranger, J. A. 2002. Gene therapy for the lysosomal storage disorders. Current Opinions in Molecular Therapeutics, 4, 349–58.Google ScholarPubMed
Charrow, J., Andersson, H. C., Kaplan, P., et al. (2004). Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. Journal of Pediatrics, 144, 112–20.CrossRefGoogle ScholarPubMed
Clarke, J. T. R. (2003). The maternal phenylketonuria project: a summary of progress and challenges for the future. Pediatrics, 112, 1584–7.Google ScholarPubMed
Cox, T. M., Aerts, F. G., Andria, G., et al. (2003). The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type II (non-neuronopathic) Gaucher disease: a position statement. Journal of Inherited Metabolic Diseases, 26, 513–526.CrossRefGoogle Scholar
Desnick, R. J. (2004). Enzyme replacement and enhancement therapies for lysosomal diseases. Journal of Inherited Metabolic Diseases, 27, 385–410.CrossRefGoogle ScholarPubMed
DiMauro, S., Mancuso, M. & Naini, A. (2004). Mitochondrial encephalomyopathies: therapeutic approach. Annals of the New York Academy of Sciences, 1011, 232–45.CrossRefGoogle ScholarPubMed
Enns, G. M. & Packman, W. (2002). The adolescent with an inborn error of metabolism: medical issues and transition to adulthood. Adolescent Medicine, 13, 315–29.Google ScholarPubMed
Frustaci, A., Chimenti, C., Ricci, R., et al. (2001). Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. New England Journal of Medicine, 345, 25–32.CrossRefGoogle ScholarPubMed
Grabowski, G. A. & Hopkin, R. J. (2003). Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. Annual Review of Genomics and Human Genetics, 4, 403–36.CrossRefGoogle ScholarPubMed
Grompe, M. (2001). The pathophysiology and treatment of hereditary tyrosinemia type 1. Seminars in Liver Disease, 21, 563–71.CrossRefGoogle ScholarPubMed
Hanley, W. B. (2004). Adult phenylketonuria. American Journal of Medicine, 117, 590–5.CrossRefGoogle ScholarPubMed
Ioannou, Y. A., Enriquez, A. & Benjamin, C. (2003). Gene therapy for lysosomal storage disorders. Expert Opinion on Biological Therapeutics, 3, 789–801.CrossRefGoogle ScholarPubMed
Koch, R., Hanley, W., Levy, H., et al. (2003). The Maternal Phenylketonuria International Study: 1984–2002. Pediatrics, 112, 1523–9.Google ScholarPubMed
Krivit, W., Peters, C. & Shapiro, E. G. (1999). Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Current Opinions in Neurology, 12, 167–76.CrossRefGoogle Scholar
Lee, P. J. (2002). Growing older: the adult metabolic clinic. Journal of Inherited Metabolic Diseases, 25, 252–60.CrossRefGoogle ScholarPubMed
MacDonald, A. (2000). Diet and compliance in phenylketonuria. European Journal of Pediatrics, 159 (Suppl 2), S136–41.CrossRefGoogle ScholarPubMed
Pastores, G. M. & Barnett, N. L. 2003. Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease type 1. Expert Opinion on Investigational Drugs, 12, 273–81.CrossRefGoogle ScholarPubMed
Pastores, G. M. & Thadhani, R. (2002). Advances in the management of Anderson-Fabry disease: enzyme replacement therapy. Expert Opinion on Biological Therapeutics, 2, 325–33.Google ScholarPubMed
Pastores, G. M., Weinreb, N. J., Aerts, H., et al. (2004). Therapeutic goals in the treatment of Gaucher disease. Seminars in Hematology, 41 (Suppl 5), 4–14.CrossRefGoogle ScholarPubMed
Peters, C., Steward, C. G.; National Marrow Donor Program; International Bone Marrow Transplant Registry; Working Party on Inborn Errors, European Bone Marrow Transplant Group. (2003). Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelinesBone Marrow Transplantation, 31, 229–39.CrossRefGoogle ScholarPubMed
Peters, C., Charnas, L. R., Tan, Y., et al. (2004). Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood, 104, 881–8.CrossRefGoogle ScholarPubMed
Platt, F. M., Jeyakumar, M., Andersson, U., et al. (2001). Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. Journal of Inherited Metabolic Diseases, 24, 275–90.CrossRefGoogle ScholarPubMed
Platt, L. D., Koch, R., Hanley, W. B., et al. (2000). The international study of pregnancy outcome in women with maternal phenylketonuria: report of a 12-year study. American Journal of Obstetrics and Gynecology, 182, 326–33.CrossRefGoogle ScholarPubMed
Rouse, B. & Azen, C. (2004). Effect of high maternal blood phenylalanine on offspring congenital anomalies and developmental outcome at ages 4 and 6 years: the importance of strict dietary control preconception and throughout pregnancy. Journal of Pediatrics, 144, 235–9.CrossRefGoogle ScholarPubMed
Russo, P. A., Mitchell, G. A. & Tanguay, R. M. (2001). Tyrosinemia: a review. Pediatric and Developmental Pathology, 4, 212–21.CrossRefGoogle ScholarPubMed
Schwahn, B. C., Hafner, D., Hohlfeld, T., Balkenhol, N., Laryea, M. D. & Wendel, U. (2003). Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria. British Journal of Clinical Pharmacology, 55, 6–13.CrossRefGoogle ScholarPubMed
Schiffmann, R. & Brady, R. O. (2002). New prospects for the treatment of lysosomal storage diseases. Drugs, 62, 733–42.CrossRefGoogle ScholarPubMed
Schon, E. A. & DiMauro, S. (2003). Medicinal and genetic approaches to the treatment of mitochondrial disease. Current Medicinal Chemistry, 10, 2523–33.CrossRefGoogle ScholarPubMed
Scriver, C. R. & Lee, P. J. (2004). The last day of the past is the first day of the future: transitional care for genetic patients. American Journal of Medicine, 117, 615–7.CrossRefGoogle ScholarPubMed
Singh, R. H., Kruger, W. D., Wang, L., Pasquali, M. & Elsas, L. J. II. (2004). Cystathionine beta-synthase deficiency: effects of betaine supplementation after methionine restriction in B6-nonresponsive homocystinuria. Genetics in Medicine, 6, 90–5.CrossRefGoogle ScholarPubMed
Hout, J. M., Kamphoven, J. H., Winkel, L. P., et al. (2004). Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics, 113, e448–57.CrossRefGoogle ScholarPubMed
Walter, J. H., Collins, J. E. & Leonard, J. V. (1999). Recommendations for the management of galactosaemia. Archives of Disease in Childhood, 80, 93–6.CrossRefGoogle ScholarPubMed
Weinreb, N. J., Aggio, M. C., Andersson, H. C., et al. (2004). Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Seminars in Hematology, 41 (Suppl 5), 15–22.CrossRefGoogle ScholarPubMed
Weinreb, N. J., Charrow, J., Andersson, H. C., et al. (2002). Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. American Journal of Medicine, 113, 112–9.CrossRefGoogle ScholarPubMed
Widaman, K. F. & Azen, C. (2003). Relation of prenatal phenylalanine exposure to infant and childhood cognitive outcomes: results from the International Maternal PKU Collaborative Study. Pediatrics, 112, 1537–43.Google ScholarPubMed
Wraith, J. E., Clarke, L. A., Beck, M., et al. (2004). Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). Journal of Pediatrics, 144, 581–8.CrossRefGoogle Scholar
Zimran, A. & Elstein, D. (2003). Gaucher disease and the clinical experience with substrate reduction therapy. Philosophical Transactions of the Royal Society London B: Biological Sciences, 358, 961–6.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Treatment
  • Joe T. R. Clarke, University of Toronto
  • Book: A Clinical Guide to Inherited Metabolic Diseases
  • Online publication: 10 September 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511544682.013
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Treatment
  • Joe T. R. Clarke, University of Toronto
  • Book: A Clinical Guide to Inherited Metabolic Diseases
  • Online publication: 10 September 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511544682.013
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Treatment
  • Joe T. R. Clarke, University of Toronto
  • Book: A Clinical Guide to Inherited Metabolic Diseases
  • Online publication: 10 September 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511544682.013
Available formats
×